Supandi Supandi, Supandi dan Yeni, Yeni In Silico Study of Pyrazolylaminoquinazoline Toxicity by Lazar, Protox, and Admet Predictor. Journal of Applied Pharmaceutical Science (8). pp. 119-129. ISSN 2231-3354
Preview |
Text
Japs-accepted.pdf Download (423kB) | Preview |
Abstract
Pyrazolylaminoquinazoline is obtained from synthetic AZD4547 and can inhibit kinase activity in recombinant
fibroblast growth factor receptor (FGFR) in vitro. The objective of this study was to obtain high activity and low
toxicity pyrazolylaminoquinazoline derivatives in silico. The 2-dimensional structures were generated using the
ChemDraw application. The Lazar application was used to predict endpoint carcinogenicity, maximum daily dose,
and mutagenicity. The ProTox application was used for endpoint LD50 and toxicity classes, while the ADMET
application was used for endpoint hepatotoxicity, with reproductive system disorders, and endocrine. Based on the
scoring from the three software applications, two compounds were identified as being active against FGFR 2, with no
carcinogenic or toxic effects on the liver, endocrine system, and the reproductive system, but they were predicted to
have mutagenic effects. These compounds were V29 (N-(5-(3,5-dimethoxy phenethyl -1H-pyrazol-3-yl)-7(octahydro-
2H-pyrido[1,2-a]pyrazine-2-yl) quinazoline-4-amine), with an IC50 of 0.2 ± 0.1 nM and a toxicity score of 1027, and
V32 (N-(5-(3,5-dimethoxy phenethyl)-1H-pyrazol-3-yl)-7-(4-(dimethylamino)piperidine-1-yl)quinazoline-4-amine),
with an IC50 of 0.3 ± 0.1 nM and a toxicity score of 1024.
| Item Type: | Article |
|---|---|
| Subjects: | R Medicine > RS Pharmacy and materia medica |
| Depositing User: | admin repository uhamka |
| Date Deposited: | 16 Oct 2018 03:19 |
| Last Modified: | 11 Jan 2019 07:09 |
| URI: | http://repository.uhamka.ac.id/id/eprint/575 |
Actions (login required)
 |
View Item |
Altmetric
Altmetric